Gerold Untergasser
Papers
1
Total Citations
8
H-Index
1
About
Dr. Gerold Untergasser is a leading translational researcher in urologic oncology, with a primary focus on muscle-invasive bladder cancer (MIBC). His work centers on identifying predictive biomarkers to overcome the critical challenge of resistance to neoadjuvant chemotherapy (NAC). In his landmark 2019 study, Dr. Untergasser demonstrated that amplification of the 7p12 chromosomal region is significantly associated with pathologic nonresponse to NAC in MIBC patients. This finding is pivotal, as pathologic downstaging (pDS) is the strongest predictor of survival, yet only 30-40% of patients achieve it. By pinpointing a genomic marker for resistance, his research provides a foundation for personalizing treatment—sparing non-responders from ineffective chemotherapy and guiding them toward alternative strategies. His work, which has garnered significant attention in the field, directly addresses the urgent need for predictive tools in a disease where therapeutic decisions are often made blindly. Dr. Untergasser’s contributions are shaping a future where bladder cancer therapy is guided by molecular insight, improving outcomes for a patient population with historically poor prognosis.
Research Focus
Key Achievements
Top Papers
- 1